|
Amendments 1 & 2...
Just to update, Amendments 1 & 2 have been issued to date. These mainly clarify RFP Q&As and confirm it will study "adults" only. The 2000(w/MDS) - 500(w/o) patients and cohorts will be studied over a five-year period. End due dates for Q&A (June 14th) and submissions (July 3rd) have been extended. 
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%  ) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
|